Log In
Print
BCIQ
Print
Print this Print this
 

PRS-110

  Manage Alerts
Collapse Summary General Information
Company Pieris AG
DescriptionAnticalin targeting c-Met receptor tyrosine kinase
Molecular Target c-Met receptor tyrosine kinase
Mechanism of Actionc-Met receptor tyrosine kinase inhibitor
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner

Zydus Cadila Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today